Patents by Inventor Anne Gurnett-Bander

Anne Gurnett-Bander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190031741
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Application
    Filed: October 15, 2018
    Publication date: January 31, 2019
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Patent number: 10125188
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 13, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Publication number: 20170029488
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 2, 2017
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Patent number: 9447173
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 20, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Publication number: 20160264650
    Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Anne Gurnett-Bander, Carlos Arrecubieta, Israel Lowy
  • Patent number: 9399674
    Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: July 26, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Anne Gurnett-Bander, Carlos Arrecubieta, Israel Lowy
  • Publication number: 20140271653
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Publication number: 20130230531
    Abstract: The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and/or duration of the primary disease, or may prevent the number, duration, and/or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, Carlos Arrecubieta, Israel Lowy